We would like to share with you the Bio/Pharma Beat, our monthly newsletter reporting on the patent law developments you should know in biotech, biologics and pharmaceutical cases, legislation and federal agency actions. This month’s issue covers relevant news from February 2020, including:
- A Federal Circuit decision applies a presumption that an express license to a patent includes an implied license to its continuations.
- A district court finds after trial that defendants’ obviousness theory had “major defects and does not come close to meeting the clear and convincing standard.”
- A district court holds that dedication-disclaimer does not apply where the allegedly dedicated subject matter is found in another claim in the same patent.
The FDA and FTC announce a collaboration “to advance competition in the biologic marketplace.”